COMP <GO>
CAH vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Cardinal Health Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CAH 2
— MRK 12
■ METRIC PARITY
LAST: $250.48 (-0.24%) • MKT CAP: $58.14B
options-implied-move
6.60%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.70% | 74.80% | -71.10 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.70% | 20.70% | +9.00 | CAH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 15.3x | +9.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.18% | 3.42% | -0.24 | MRK | /fcf-yield <GO> |
| Operating Margin | 1.00% | 34.30% | -33.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.70% | 28.10% | -27.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -1.90% | 1.30% | -3.20 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.85% | 2.26% | -1.41 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.19 | -0.03 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 56.9 | +1.59 | CAH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 0.92 | -0.02 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.6x | 18.4x | +16.20 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $58.14B | $361.02B | -$302.88B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAH REV | MRK REV | CAH GROSS % | MRK GROSS % | CAH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $222.58B | $65.01B | 3.7% | 74.8% | $1.85B | $12.36B |
| FY 2024 | $226.83B | $64.17B | 3.3% | 76.3% | $3.25B | $18.10B |
| FY 2023 | $204.98B | $60.12B | 44.0% | 44.0% | -$6.38B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAH // BETA 0.90
MRK // BETA 0.92